Search results
Predicting Right Ventricular Failure after LVAD Implantation
Author(s):
Parth Visrodia
,
Aniket S Rali
,
Gabriel Hernandez
,
et al
Added:
4 months ago
Original Research
Heart Failure in Hypertrophic Cardiomyopathy
Author(s):
Olives Nguyen
,
Daniel Kamna
,
Ahmad Masri
Added:
3 days ago
Review Article
Author(s):
Dominic Marcel Alfonso
Added:
2 weeks ago
Author(s):
Archana Ganapathy
,
Jason N Dungu
,
Anthony D Dimarco
,
et al
Added:
2 weeks ago
Author(s):
Sanjeev Gulati
Added:
2 months ago
The Role of GLP-1 in Heart Failure
Author(s):
Amina Rakisheva
,
Anton Zatsarinnyy
Added:
3 weeks ago
Editorial
Author(s):
Ambarish Pandey
Added:
3 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents findings from a randomized clinical trial comparing medically tailored meals versus produce supplements on heart failure readmissions and emergency department visits.The study was conducted across two centers in Dallas, Texas. Patients were randomized within two weeks following heart…
View more
Author(s):
Ambarish Pandey
Added:
3 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not…
View more
Author(s):
Diana Hui Ping Foo
Added:
9 months ago
ESC HF 25 - Findings from Heart2Miss suggest a hub-and-spoke model for early heart failure detection can detect patients with pre-HF and HF who were previously undiagnosed, can reduce tertiary center overload and improve novice performance.Dr Diana Foo (Sarawak General Hospital, Kuching, MY) discusses the findings from the Heart2Miss study, investigating a decentralised, community-based, rapid,…
View more
Author(s):
Stephen J Greene
Added:
9 months ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an…
View more
